Additional file 2 of CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1

Additional file 2: Supplementary Figure S2. CDK16 knockdown induces proliferation inhibition in TNBC and HR+ cells but not in HER2+ breast cancer cells. A-B Immunoblot analysis to verify CDK16 knockdown in indicated TNBC cells (A) and in HR+ and HER2+ breast cancer cells (B) transfected with two individual CDK16-shRNAs. C 2D-colony formation assay of indicated HR+ and HER2+ cells with CDK16-KD. Shown are representative images (scale bar, 100 μm, left panel) and quantification of colonies (right panel). D Apoptosis analysis of indicated TNBC cells with CDK16-KD. Shown are FACS results (left panel) and statistics of cells in early apoptosis (right panel). E Cell cycle analysis of indicated TNBC cells with CDK16-KD. Shown are FACS results (left panel) and statistics of cells in specific phases (right panel). Data are shown as mean ± SD and p values were obtained by two-tailed Student’s t-test. All *p